#1 Clinical Trials Search in Europe

89ZR-CED88004S

Clinical trials are studying 89ZR-CED88004S in people with large B-cell lymphoma. These trials aim to see how well PET imaging can show CD8+ T-cells before and after CAR T-cell therapy, and to measure how the tracer is distributed in the body and tumors.

Table of Contents

Trial overview

The trial titled CD8 PET imaging study before and after CAR T-cell therapy is studying 89ZR-CED88004S in people with large B-cell lymphoma.[1] It is an interventional study, which means the research team gives the tracer and then measures the results on imaging scans.[1]

The study is authorised and plans to enroll 27 people.[1] The source data describes 89ZR-CED88004S as part of a PET imaging approach used before and after CAR T-cell therapy.[1]

Who can participate

The target population in this trial is people with large B-cell lymphoma, a cancer of B cells, which are a type of white blood cell.[1] The source data does not list more detailed entry rules, such as age limits or prior treatments.[1]

The study focuses on patients before and after CAR T-cell therapy, so the imaging is meant to follow changes over time in the same disease setting.[1]

What is being measured

The main outcome is the whole-body biodistribution of the tracer, which means how the tracer spreads through normal tissues and tumor lesions across the body.[1] The study also measures heterogeneity, meaning whether the tracer signal is the same or different in different areas.[1]

Another key measure is standardized uptake value (SUV) on the PET scan 2 days after injection.[1] SUV is a number used to show how much tracer is taken up by a tissue or lesion.[1]

The brief summary says the study will correlate, or compare, the pretreatment CD8+ T-cell pattern with CD8+ CAR T-cell tumor invasion, as shown by the intensity of PET-positive lesions.[1]

Study design and phase

This is a Phase 4 trial.[1] Phase 4 studies are generally used to learn more about a test or treatment in a broader clinical setting after it is already being used.[1]

The intervention listed is 89ZR-CED88004S given as a 10 mg intravenous bolus injection or IV infusion.[1] The source data does not provide further details about the full scan schedule beyond the PET scan 2 days after injection.[1]

Why this study matters

This trial is trying to see whether PET imaging with 89ZR-CED88004S can show where CD8+ T-cells are located before treatment and how they change after CAR T-cell therapy.[1] That may help researchers understand how immune cells move into tumors during treatment.[1]

For patients, the important point is that this study is not mainly about treating the cancer directly.[1] It is about using imaging to learn more about the immune response in large B-cell lymphoma.[1]

Trial ID Phase Condition studied Status Enrollment
2025-520560-18-00 Phase 4 Large B-cell lymphoma Authorised 27

FAQ

  • What is being studied in the 89ZR-CED88004S trial? The trial is studying PET imaging with 89ZR-CED88004S to see where CD8+ T-cells are found in the body. It also looks at how the tracer appears in normal tissues and tumor lesions before and after CAR T-cell therapy.
  • Who can take part in this trial? The trial is for people with large B-cell lymphoma. The source data does not give more details about age, prior treatment, or other entry rules.
  • What phase is the trial? This is a Phase 4 trial. Phase 4 studies are usually done after a treatment or test is already in use, to learn more in a real-world setting.
  • What main result is the trial measuring? The main result is the whole-body distribution of the tracer in normal tissues and tumor lesions. The study also measures tracer uptake, which means how much of the tracer is seen in different areas on the PET scan.
  • What does CAR T-cell therapy have to do with this trial? The trial compares PET findings before and after CAR T-cell therapy. It aims to correlate, or match up, the CD8+ T-cell pattern before treatment with how CAR T-cells invade the tumor after treatment.

Ongoing Clinical Trials on 89ZR-CED88004S

  • PET Imaging Study for Large B-Cell Lymphoma Patients Using 89Zr-CED88004S Before and After CAR T-Cell Therapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Large B-cell lymphoma: A type of cancer that starts in B cells, which are a kind of white blood cell.
  • CD8+ T-cells: A type of immune cell that helps the body fight disease. The trial is looking at where these cells are found.
  • CAR T-cell therapy: A treatment that uses specially changed T-cells to attack cancer cells.
  • PET imaging: A scan that shows how a tracer moves through the body and where it builds up.
  • Tracer: A substance used in imaging to help show certain cells or tissues on a scan.
  • Whole-body biodistribution: How a tracer spreads through the whole body and where it collects.
  • Tumor lesions: Areas of cancer seen in the body.
  • Standardized uptake value (SUV): A number used on PET scans to show how much tracer is taken up by a tissue.
  • Uptake: How much of the tracer is taken in or seen in a tissue on the scan.
  • Heterogeneity: Differences from one area to another. In this trial, it means the tracer may not appear the same in every lesion or tissue.

References

  1. https://clinicaltrials.gov/study/2025-520560-18-00